Containing Solid Synthetic Polymers Patents (Class 424/497)
  • Patent number: 11491123
    Abstract: Provided is a method of inhibiting viral replication, including contacting one or more cells that has been infected or contacted with a flavivirus with an effective amount of niclosamide, temoporfin, nitazoxanide, tizoxanide, erythrosin B, methylene blue. Contacting one or more cells that have been infected with a flavivirus may include administering the compound to a mammal, a human, or other subject. The flavivirus may be Dengue virus serotype 1, Dengue virus serotype 2, Dengue virus serotype 3, Dengue virus serotype 4, yellow fever virus, West Nile virus, Zika virus, Japanese encephalitis virus, tick-born encephalitis virus, Powassan virus, St. Louis encephalitis virus, or other flavivirus.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: November 8, 2022
    Assignees: HEALTH RESEARCH, INC., THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Hongmin Li, Laura D. Kramer, Zhong Li, Ruili Huang, Menghang Xia
  • Patent number: 11464860
    Abstract: Provided herein are branched poly(beta-amino esters) (PBAE) useful as vehicles for the delivery of therapeutic agents, such as nucleic acids. The disclosed polymers form stable compositions, and are suitable for the delivery of therapeutic agents via nebulization. Compositions of the disclosed polymers are capable of delivering therapeutic agents such as mRNA to lung epithelial cells.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: October 11, 2022
    Assignee: Massachusetts Institute of Technology
    Inventors: Daniel Griffith Anderson, Kevin John Kauffman, James C. Kaczmarek, Asha Kumari Patel
  • Patent number: 11464748
    Abstract: This disclosure relates to microcapsule particles for targeted delivery of drugs. In certain embodiments, the particles comprise polyelectrolyte polymers, e.g., layers of anionic polymers and cationic polymers. In certain embodiments, the particles have a fibrinogen coating. In certain embodiments, the particles contain a polysaccharide core and/or a polysaccharide coating encapsulating drugs, proteins, clotting agents, coagulation factors, or anticoagulants. In certain embodiments, this disclosure contemplates methods of using particles disclosed herein to prevent or reduce onset of or duration of bleeding. In certain embodiments, this disclosure contemplates methods of using particles disclosed herein to prevent or reduce onset of blood clotting.
    Type: Grant
    Filed: January 31, 2017
    Date of Patent: October 11, 2022
    Assignees: Emory University, Children's Healthcare of Atlanta, Inc., Georgia Tech Research Corporation, Chapman University
    Inventors: Wilbur A. Lam, Caroline Hansen, Yumiko Sakurai, Andrew Lyon
  • Patent number: 11426351
    Abstract: A pharmaceutical composition having consistently a desirable release rate is prepared by controlling the finally mixing time based on the molecular weight measured in the intermediate product. The pharmaceutical composition includes micro particles containing a polyhydric alcohol, a salt, a water-soluble polymer and a pharmaceutically active ingredient. The micro particles are dispersed in a matrix of a hydrophobic ingredient and an amphipathic ingredient.
    Type: Grant
    Filed: December 26, 2019
    Date of Patent: August 30, 2022
    Assignee: SUNSTAR INC.
    Inventors: Mayo Araki, Rie Tanaka, Youko Takeda
  • Patent number: 11350657
    Abstract: A gummy composition including: 10 to 45 percent by weight of the composition of a protein, wherein a portion of the protein is hydrolyzed; Maltitol syrup; sugar; a structurant; and Water. A method of manufacture of a gummy composition including: Forming a mixture comprising 10 to 45 percent by weight of the composition of a protein, maltitol syrup, sugar, a structurant and water, wherein a portion of the protein is hydrolyzed; and cooking the mixture at a temperature of 85° C. or less.
    Type: Grant
    Filed: August 6, 2018
    Date of Patent: June 7, 2022
    Assignee: PHARMAVITE, LLC
    Inventors: Haiyan Ge, Edward Shneyvas
  • Patent number: 11352447
    Abstract: Gellan gum-based hydrogels are disclosed herein for in vitro cell culture and tissue engineering and regenerative medicine applications. Such gellan gum-based hydrogels may be used alone or combined with live cells and/or biomolecules for application in humans and/or animals. Chemical modification of gellan gum with selected ion-chelating substituents affords novel gellan gum hydrogels endowed with tunable physicochemical and biological properties. The modified gellan gum hydrogels described herein present advantages over existing hydrogel systems, including solubility, ionic crosslinking versatility, ease of formulation and injectability and greater adhesiveness within biological tissues and surfaces, whilst maintaining encapsulated cells viable during long culture periods and up-regulating the expression of healthy extracellular matrix markers.
    Type: Grant
    Filed: March 24, 2017
    Date of Patent: June 7, 2022
    Assignee: STEMMATTERS, BIOTECNOLOGIA E MEDICINA REGENERATIVA, S.A.
    Inventors: Rui Pedro Romero Amandi De Sousa, Cristina Correia, David Alexander Learmonth
  • Patent number: 11311651
    Abstract: Provided are an absorbable biomedical composite material and a preparation method therefor. The absorbable biomedical composite material comprises: substrate granules containing a calcium-phosphorus compound; an intermediate layer which is coated on the surface of each of the substrate granules and has a first glass transition temperature, the first glass transition temperature being not higher than normal human body temperature; and a polymer matrix which is formed on the outer surface of the intermediate layer and has a second glass transition temperature, the second glass transition being higher than the first glass transition temperature. The absorbable biomedical composite material has increased mechanical strength and also improved toughness.
    Type: Grant
    Filed: July 15, 2018
    Date of Patent: April 26, 2022
    Assignee: SHENZHEN CORLIBER SCIENTIFIC CO., LTD.
    Inventors: Yang Sun, Feng Pan, Yucheng Huang, Dong Xiang
  • Patent number: 11286390
    Abstract: The invention relates to novel antimicrobial surfactants and their application in antimicrobial coating systems, in particular water borne coatings. Provided is a method for providing an antimicrobial surfactant, comprising the steps of: (a) providing a hyperbranched polyurea having blocked isocyanates at the end of the polymer branches by the polycondensation of AB2 monomers; (b) introducing tertiary amine groups by reacting said blocked isocyanates of the hyperbranched polyurea with a tertiary amine compound that is functionalized with —OH, —NH2, —SH, or —COO—; and (c) quaternization of said tertiary amine groups by reacting with an alkylating agent to obtain a quaternized hyperbranched polymer having antimicrobial surfactant properties.
    Type: Grant
    Filed: September 7, 2017
    Date of Patent: March 29, 2022
    Assignee: Van Wijhe Beheer B.V.
    Inventors: Bram Fieten, Jan Wessels, Rainier Antonius Hermanus Brookhuis, Marie Louise Van Wijhe, Jacobus Antonius Loontjens, Pei Zhao, Hendrik Jan Busscher, Henderina Catharina Van Der Mei, Stefan Wouter Wessel, Francesco Mecozzi, Marianne Driesse
  • Patent number: 11266768
    Abstract: The disclosure provides a drug delivery device that can release a drug or other molecule of interest in response to application of a mechanical force, such as tension, and methods of use thereof. The present disclosure provides a tension-responsive drug delivery device by exploiting a difference in mechanical properties between a drug-loaded core material and a supertiydrophobic barrier coating consisting of interconnected micro- and nano-sized particles formulated via the electrospraying of a mixture of biocompatible polymers.
    Type: Grant
    Filed: November 26, 2014
    Date of Patent: March 8, 2022
    Assignee: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Mark Grinstaff, Jonah Andrew Kaplan, Julia Wang
  • Patent number: 11261858
    Abstract: Fill stations and base stations are provided for personal pump systems. The fill stations may be opened and closed to accept a reservoir and to allow fluid to be introduced into the reservoir for use with personal pump systems. The fill stations may hold the reservoir at a tilt relative to an underlying surface and may discourage overfilling of the reservoir. The filling stations may also include viewing windows having fluid lines marked thereon for indicating volume of fluid within the reservoir.
    Type: Grant
    Filed: November 13, 2020
    Date of Patent: March 1, 2022
    Assignee: DEKA PRODUCTS LIMITED PARTNERSHIP
    Inventors: Dean Kamen, Larry B. Gray, Russell H. Beavis
  • Patent number: 11236582
    Abstract: Capsules with a cement additive covered by a polymeric outer shell are added to wellbore cement. The additive is released from the shells by osmosis or shell ruptures. Capillary forces draw the additive into micro-annuli or cracks present in the cement, where the additive seals the micro-annuli and cracks to define a self-sealing material. The empty shells remain in the cement and act as an additive that modifies cement elasticity. The capsules are formed by combining immiscible liquids, where one of the liquids contains a signaling substance, and each of the liquids contains a reagent. When combined, the liquids segregate into a dispersed phase and a continuous phase, with the dispersed phase having the signaling agent. The reagents react at interfaces between dispersed and continuous phases and form polymer layers encapsulating the signaling agent to form the capsules. Adjusting relative concentrations of the reagents varies membrane strength and permeability.
    Type: Grant
    Filed: September 17, 2018
    Date of Patent: February 1, 2022
    Assignee: SAUDI ARABIAN OIL COMPANY
    Inventor: Elizabeth Q. Contreras
  • Patent number: 11185835
    Abstract: Porous metal oxide microspheres are prepared via a process comprising forming a liquid solution or dispersion of polydisperse polymer nanoparticles and a metal oxide; forming liquid droplets from the solution or dispersion; drying the liquid droplets to provide polymer template microspheres comprising polymer nanospheres and metal oxide; and removing the polymer nanospheres from the template microspheres to provide the porous metal oxide microspheres. The porous microspheres exhibit saturated colors and are suitable as colorants for a variety of end-uses.
    Type: Grant
    Filed: September 10, 2018
    Date of Patent: November 30, 2021
    Assignees: BASF SE, PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Rupa Hiremath Darji, James Newhouse, Vinothan N. Manoharan, Victoria Hwang, Anna B. Stephenson
  • Patent number: 11179694
    Abstract: Porous metal oxide microspheres are prepared via a process comprising forming a liquid dispersion of polymer nanoparticles and a metal oxide; forming liquid droplets of the dispersion; drying the droplets to provide polymer template microspheres comprising polymer nanospheres; and removing the polymer nanospheres from the template microspheres to provide the porous metal oxide microspheres. The porous microspheres exhibit saturated colors and are suitable as colorants for a variety of end-uses.
    Type: Grant
    Filed: September 10, 2018
    Date of Patent: November 23, 2021
    Assignees: BASF SE, PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Rupa Hiremath Darji, James Newhouse, Vinothan N. Manoharan, Victoria Hwang, Anna B. Stephenson
  • Patent number: 11124758
    Abstract: The present invention has publicized a bacteria culture medium. In common bacteria culture medium, one kind or several kinds of ?-lactam antibiotics and/or the salts thereof were premixed. The ?-lactam antibiotics and/or the salts thereof premixed in the bacteria culture medium is slightly soluble in water at 25° C. and the solubility is less than 10 mg/ml. The concentrations of the ?-lactam antibiotics premixed in the culture medium are greater than the solubility of the used ?-lactam antibiotics at 25° C., but are less than 100 mg/ml. The bacteria culture medium can be used to selectively culture bacteria with ?-lactam antibiotic resistance and can be stored for a long time.
    Type: Grant
    Filed: October 15, 2013
    Date of Patent: September 21, 2021
    Assignee: SHANGHAI PROMOTON BIOTECHNOLOGY CO., LTD.
    Inventors: Botao Zhao, Chunhai Cai, Guoquan Zhou, Dehua Yang, Jin Liu
  • Patent number: 11071975
    Abstract: Disclosed is a system and method of treatment which provides a direct response to the treatment of pneumonia as related to infections using a powder comprising a polyiodide resin with broad spectrum bactericidal, fungicidal and virucidal properties. When the powder is applied directly to the lungs of a mammal an immediate contact kill of protozoa, bacteria, fungi and viruses that cause respiratory tract infections affecting the lungs of a mammal takes place. Also disclosed is an application of the polyiodide resin powder for use with personal protective equipment (PPE) including but not limited to face masks, face shields, and respirators.
    Type: Grant
    Filed: August 31, 2020
    Date of Patent: July 27, 2021
    Inventors: Albert Rego, Lynn R. Detlor, Aileen Law
  • Patent number: 11065187
    Abstract: A method for forming a photosensitizer product that is resistant to absorption by living tissue that may include binding a photosensitizer compound with an oxide-containing particle to provide the photosensitizer derivative having a microscale size, and mixing the photosensitizer derivative into a lotion. The microscale size of the photosensitizer derivative obstructs absorption by cell tissue.
    Type: Grant
    Filed: July 16, 2019
    Date of Patent: July 20, 2021
    Assignee: International Business Machines Corporation
    Inventors: Scott B. King, Brandon M. Kobilka, Joseph Kuczynski, Jacob T. Porter, Jason T. Wertz
  • Patent number: 11066571
    Abstract: It is an object of the present invention to provide a pattern forming method capable of easily forming a phase-separated structure with high accuracy, even in the case of widening the applicable range of a pattern size. The present invention relates to a pattern forming method comprising: applying an under coating agent onto a substrate, and applying a self-assembly composition for pattern formation to the surface of the substrate, onto which the under coating agent has been applied, and then forming a self-assembly film according to self-assembly phase separation, wherein the self-assembly composition for pattern formation comprises a block copolymer comprising a polymerization unit (a) having at least one selected from a structure represented by a formula (103) and a structure represented by a formula (104), and a polymerization unit (b) having a structure represented by a formula (105).
    Type: Grant
    Filed: May 30, 2017
    Date of Patent: July 20, 2021
    Assignee: OJI HOLDINGS CORPORATION
    Inventors: Kazuyo Morita, Kimiko Hattori
  • Patent number: 11046823
    Abstract: Provided herein are improved compositions and methods of making and using the same, the composition comprising a polymer and a ceramic present at a ratio of from 3:1 to 1:3 of polymer:ceramic by weight, wherein the composition comprises or is a composite of the polymer and the ceramic having improved printability and/or having an improved elastic modulus and/or improved stress at failure (e.g., as compared to a blend of the polymer and the ceramic).
    Type: Grant
    Filed: August 2, 2017
    Date of Patent: June 29, 2021
    Assignee: WAKE FOREST UNIVERSITY HEALTH SCIENCES
    Inventor: Carlos Kengla
  • Patent number: 11020711
    Abstract: A membrane for filtering one or more hydrophobic organic contaminants can include a porous nanostructure that includes one or more of a metal, a metal oxide, and a metal alloy nanostructure component functionalized with one or more amphiphilic ligands.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: June 1, 2021
    Assignee: UCHICAGO ARGONNE, LLC
    Inventors: Xiao-Min Lin, Kun Wu, Subramanian Sankaranarayanan
  • Patent number: 10940177
    Abstract: Provided herein are stable lisinopril oral liquid formulations. Also provided herein are methods of using lisinopril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and acute myocardial infarction.
    Type: Grant
    Filed: March 18, 2020
    Date of Patent: March 9, 2021
    Assignee: SILVERGATE PHARMACEUTICALS, INC.
    Inventors: Gerold L. Mosher, David W. Miles
  • Patent number: 10856566
    Abstract: Embodiments of the invention are related generally to compositions comprising Co-Q10, a source of omega-3 fatty acids, and vitamin D, and methods of making thereof. In particular, the invention relates to stable compositions comprising Co-Q10, krill oil, vitamin D, and an antioxidant suitable for use as dietary supplements, and methods of making thereof. The compositions may further comprise an emulsifier to impart stability to the compositions.
    Type: Grant
    Filed: February 24, 2016
    Date of Patent: December 8, 2020
    Assignee: RB HEALTH (US) LLC
    Inventors: Ed Derohanes, Kenneth Rayl, Michal Siwek, John Williams
  • Patent number: 10857103
    Abstract: A delayed release drug formulation includes a core and a coating. The coating includes a mixture of a first material selected from starch; amylose; amylopectin; chitosan; chondroitin sulfate; cyclodextrin; dextran; pullulan; carrageenan; scleroglucan; chitin; curdulan and levan, and a second material which has a pH threshold at about pH 5 or above. The delayed release drug formulation is used to target release of a drug from a core to the intestine, particularly the colon.
    Type: Grant
    Filed: April 17, 2020
    Date of Patent: December 8, 2020
    Assignee: UNIVERSITY COLLEGE LONDON
    Inventors: Abdul Basit, Valentine Ibekwe
  • Patent number: 10828260
    Abstract: The present invention provides, in part, formulations comprising a beta-lactamase. Particularly, modified-release formulations comprising a beta-lactamase are provided which release a substantial amount of the beta-lactamase in the intestines. Therapeutic uses of the beta-lactamase formulations are also provided.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: November 10, 2020
    Assignee: Synthetic Biologics, Inc.
    Inventors: Andrew Bristol, Michael Kaleko, Sheila Connelly
  • Patent number: 10786511
    Abstract: The present invention relates to pharmaceutical compositions comprising inhibitor(s) of human histone methyltransferase EZH2, and methods of cancer therapy using the EZH2 inhibitor(s).
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: September 29, 2020
    Assignees: Epizyme, Inc., Eisai R&D Management Co., Ltd.
    Inventors: Heike Keilhack, Brett Truitt, Yuta Suzuki, Tsukasa Murase, Futoshi Shikata
  • Patent number: 10758491
    Abstract: A delayed release coating includes a mixture of a first material selected from starch; amylose; amylopectin; chitosan; chondroitin sulfate; cyclodextrin; dextran; pullulan; carrageenan; scleroglucan; chitin; curdulan and levan, and a second material which has a pH threshold at about pH 5 or above. The delayed release coating is used to target release of a drug from a core to the intestine, particularly the colon.
    Type: Grant
    Filed: February 24, 2020
    Date of Patent: September 1, 2020
    Assignee: University College London
    Inventors: Abdul Basit, Valentine Ibekwe
  • Patent number: 10758480
    Abstract: Disclosed is a system and method of treatment which provides a direct response to the treatment of pneumonia as related to infections using a powder comprising a polyiodide resin with broad spectrum bactericidal, fungicidal and virucidal properties. When the powder is applied directly to the lungs of a mammal an immediate contact kill of protozoa, bacteria, fungi and viruses that cause respiratory tract infections affecting the lungs of a mammal takes place.
    Type: Grant
    Filed: April 9, 2020
    Date of Patent: September 1, 2020
    Assignee: VALENCIDE LLC
    Inventors: Albert Rego, Lynn R. Detlor
  • Patent number: 10656147
    Abstract: Methods and apparatus for processing fluids on a macro- or micro-scale are described. In various aspects, a fluid may have a plurality of elongated (i.e., substantially rod-shaped) magnetic elements disposed therein within a fluid container. An illustrative fluid container is an actuator electrode or a processing vial of a microfluidic device, such as a digital microfluidic device. A magnet component may be configured to generate a magnetic force sufficient to influence the movement of the plurality of elongated magnetic elements within the fluid to be processed. For example, the magnetic force (or magnetic force gradient) may influence the plurality of elongated magnetic elements to rotate, spin, and/or move laterally side-to-side. The shape and movements of the plurality of elongated magnetic elements facilitate the rapid and efficient processing of the fluid, such as fluid mixing and/or fluid separation.
    Type: Grant
    Filed: February 27, 2015
    Date of Patent: May 19, 2020
    Assignee: DH Technologies Development Pte. Ltd.
    Inventors: John L. Campbell, Thomas R. Covey, Chang Liu, Subhasish Purkayastha
  • Patent number: 10561621
    Abstract: A composition comprising a core material, having a taste value and a polymeric coating. The polymeric coating substantially surrounds the core material and comprises a cationic polymer and optionally an anionic polymer. The polymeric coating has a uniform thickness ranging from 2 ?m to 20 ?m. The composition provides release of a portion of the core material which is taste masked over a time period ranging from 0.5 minute to 2 minutes in the oral cavity and provides a modified-release of the remaining core material in a gastrointestinal tract.
    Type: Grant
    Filed: September 20, 2011
    Date of Patent: February 18, 2020
    Inventors: Diane Goll, Cecil W. Propst
  • Patent number: 10543203
    Abstract: There is provided a sustained-release pharmaceutical composition comprising a solid, continuous network comprising an excipient with a high mechanical strength, which network also comprises pores, within which pores is interspersed a mixture of an active ingredient and a film-forming agent, characterised in that said pores are formed during the production of the composition. Compositions of the invention find particularly utility as abuse-resistant formulations comprising opioid analgesics that may be employed in the treatment of chronic pain.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: January 28, 2020
    Assignee: Emplicure AB
    Inventors: Susanne Bredenberg, Anna Dahlgren, Anders Sågström, Håkan Engqvist
  • Patent number: 10545135
    Abstract: The present invention relates to a pharmaceutical composition comprising of preparations of human embryonic stem (hES) cells and their derivatives and methods for their transplantation into the human body, wherein transplantation results in the clinical reversal of symptoms, cure, stabilization or arrest of degeneration of a wide variety of presently incurable and terminal medical conditions, diseases and disorders. The invention further relates to novel processes of preparing novel stem cell lines which are free of animal products, feeder cells, growth factors, leukaemia inhibitory factor, supplementary mineral combinations, amino acid supplements, vitamin supplements, fibroblast growth factor, membrane associated steel factor, soluble steel factor and conditioned media. This invention further relates to the isolation, culture, maintenance, expansion, differentiation, storage, and preservation of such stem cells.
    Type: Grant
    Filed: March 6, 2007
    Date of Patent: January 28, 2020
    Inventor: Geeta Shroff
  • Patent number: 10543285
    Abstract: In one aspect, methods of targeted nanoparticle and cell delivery are described herein. In some embodiments, methods described herein comprise coupling nanoparticles and cells to a carrier cell to form a nanoparticle-cell conjugate or cell-cell conjugate, disposing the nanoparticle-cell or cell-cell conjugate in a biological environment, and delivering the nanoparticles and cells to target cells or tissues located within the biological environment. The nanoparticles comprise a biodegradable photoluminescent polymer, and the nanoparticle-cell conjugate is formed using one or more click chemistry reaction products.
    Type: Grant
    Filed: April 13, 2017
    Date of Patent: January 28, 2020
    Assignee: The Penn State Researh Foundation
    Inventors: Jian Yang, Cheng Dong, Zhiwei Xie
  • Patent number: 10517962
    Abstract: The invention relates to a novel use of ultrafine nanoparticles, of use as a diagnostic, therapeutic or theranostic agent, characterized by their mode of administration via the airways. The invention is also directed toward the applications which follow from this novel mode of administration, in particular for imaging the lungs, and the diagnosis or prognosis of pathological pulmonary conditions. In the therapeutic field, the applications envisioned are those of radiosensitizing or radioactive agents for radiotherapy (and optionally curietherapy), or for neutron therapy, or of agents for PDT (photodynamic therapy), in particular for the treatment of lung tumors.
    Type: Grant
    Filed: April 12, 2013
    Date of Patent: December 31, 2019
    Assignees: Universite Claude Bernard Lyon I, Nano-H, Universite Grenoble Alpes, Universite de Bordeaux, Centre National de la Recherche Scientifique
    Inventors: Yannick Cremillieux, Andrea Bianchi, Sandrine Dufort, Jean-Luc Coll, Francois Lux, Olivier Tillement
  • Patent number: 10363309
    Abstract: A composition for treating a disorder in a subject includes a polyethylene glycolylated (PEGylated) nanoparticle, at least one hydrophobic therapeutic agent coupled to the surface of the nanoparticle; and at least one targeting moiety coupled to polyethylene glycol of the nanoparticle for targeting the composition to a cell associated with disorder.
    Type: Grant
    Filed: February 5, 2012
    Date of Patent: July 30, 2019
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: James Basilion, Clemens Burda
  • Patent number: 10293077
    Abstract: A hemostatic composition is provided. The hemostatic composition includes a hemostatically effective amount of a hemostatic agent that includes a nanoparticle and a polyphosphate polymer attached to the nanoparticle. Also provided are medical devices and methods of use to promote blood clotting.
    Type: Grant
    Filed: October 14, 2015
    Date of Patent: May 21, 2019
    Assignees: The Regents of the University of California, The Board of Trustees of the University of Illinois
    Inventors: Damien Kudela, Galen D. Stucky, Anna May-Masnou, Gary Bernard Braun, James H. Morrissey, Stephanie A. Smith
  • Patent number: 10238709
    Abstract: Methods of treating acromegaly in a subject are described herein. Exemplary methods include orally administering to the subject at least once daily at least one dosage form comprising octreotide, wherein the octreotide in each dosage form is 20 mg, and wherein the administering occurs at least 1 hour before a meal or at least 2 hours after a meal.
    Type: Grant
    Filed: February 3, 2016
    Date of Patent: March 26, 2019
    Assignee: Chiasma, Inc.
    Inventors: Roni Mamluk, Sam L. Teichman
  • Patent number: 10206882
    Abstract: Compositions of the present invention, comprising at least one digestive enzyme (e.g., pancrelipase) are useful for treating or preventing disorders associated with digestive enzyme deficiencies. The compositions of the present invention can comprise a plurality of coated particles, each of which is comprised of a core coated with an enteric coating comprising at least one enteric polymer and 4-10% of at least one alkalinizing agent, or have moisture contents of about 3% or less, water activities of about 0.6 or less, or exhibit a loss of activity of no more than about 15% after six months of accelerated stability testing.
    Type: Grant
    Filed: October 2, 2013
    Date of Patent: February 19, 2019
    Assignee: ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED
    Inventors: Giovanni Ortenzi, Marco Marconi, Luigi Mapelli
  • Patent number: 10207003
    Abstract: Provided herein are amphiphilic polymers compositions for making aqueous formulations. In one aspect, a solution composition for delivery and release of active ingredients comprises a block co-polymer having formula: PEG-PCL-PLA-PCL-PEG or PGA-PCL-PEG-PCL-PGA or PLA-PCL-PEG-PCL-PLA or PCL-PLA-PEG-PLA-PCL or PCL-PGA-PEG-PGA-PCL. The block co-polymers are biodegradable, stable and compatible with hydrophilic, hydrophobic, and combinations thereof, biologic or chemical active agents. In some embodiments, the block co-polymers enable sustained and/or continuous release of various active agents. In certain embodiments, the block co-polymers can be used to make an artificial tear preparation, a lubricant for joints or wound cover or adhesive.
    Type: Grant
    Filed: April 29, 2017
    Date of Patent: February 19, 2019
    Assignee: inovion, Inc.
    Inventors: Poonam R. Velagaleti, Brian C. Gilger, Ulrich Grau, Rasidul Amin, Santhi Abbaraju
  • Patent number: 10195571
    Abstract: Multiple emulsions and techniques for the formation of multiple emulsions are generally described. A multiple emulsion, as used herein, describes larger droplets that contain one or more smaller droplets therein. In some embodiments, the larger droplet or droplets may be suspended in a carrying fluid containing the larger droplets that, in turn, contain the smaller droplets. As described below, multiple emulsions can be formed in one step in certain embodiments, with generally precise repeatability, and can be tailored in some embodiments to include a relatively thin layer of fluid separating two other fluids.
    Type: Grant
    Filed: August 12, 2016
    Date of Patent: February 5, 2019
    Assignee: President and Fellows of Harvard College
    Inventors: David A. Weitz, Shin-Hyn Kim, Alireza Abbaspourrad
  • Patent number: 10183001
    Abstract: An abuse deterrent drug product is provided wherein the drug product comprises a matrix and a drug substance in the matrix wherein the drug substance is defined as a 1:1 salt of a pharmaceutically active compound and BNDO.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: January 22, 2019
    Assignee: Pisgah Laboratories, Inc.
    Inventors: Clifford Riley King, Stephen G. D'Ambrosio, David W. Bristol
  • Patent number: 10172956
    Abstract: The presently-disclosed subject matter includes nanoparticles that comprise a plurality of assembled polymers. In some embodiments the polymers comprise a first block that includes hydrophilic monomers, the first block substantially forming an outer shell of the nanoparticle, and a second block that includes cationic monomers and hydrophobic monomers, the second block substantially forming a core of the nanoparticle. In some embodiments a polynucleotide is provided that is bound to the cationic monomers of the nanoparticle. The presently-disclosed subject matter also comprises methods for using the present nanoparticles to include RNAi in a cell as well as methods for making the present nanoparticles.
    Type: Grant
    Filed: October 28, 2013
    Date of Patent: January 8, 2019
    Assignee: Vanderbilt University
    Inventors: Craig L. Duvall, Christopher E. Nelson, James Kintzing, Joshua M. Shannon, Mukesh K. Gupta, Scott A. Guelcher, Elizabeth J. Adolph, Jeffrey M. Davidson
  • Patent number: 10159661
    Abstract: The present invention is directed to an injection syringe comprising an injectable composition, the composition comprising a penicillin, salt or prodrug thereof, one or more pharmaceutically acceptable excipients, and water, wherein the composition is free of a preservative agent. In other aspects, the invention relates to a process for producing the injection syringe, and a kit comprising the injection syringe.
    Type: Grant
    Filed: February 22, 2016
    Date of Patent: December 25, 2018
    Assignee: Sandoz AG
    Inventors: Christoph Bitter, Heiko Degendorfer, Johannes Raneburger
  • Patent number: 10105322
    Abstract: The present invention provides, in part, formulations comprising a beta-lactamase. Particularly, modified-release formulations comprising a beta-lactamase are provided which release a substantial amount of the beta-lactamase in the intestines. Therapeutic uses of the beta-lactamase formulations are also provided.
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: October 23, 2018
    Assignee: SYNTHETIC BIOLOGICS, INC.
    Inventors: Andrew Bristol, Michael Kaleko, Sheila Connelly
  • Patent number: 10076572
    Abstract: Effective Photodynamic therapy (PDT) against C. difficile is provided using a composition including chitosan and tetracycline.
    Type: Grant
    Filed: April 17, 2015
    Date of Patent: September 18, 2018
    Assignee: CATHOLIC UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION
    Inventors: Hiun Suk Chae, Sung Sook Choi
  • Patent number: 10046065
    Abstract: A nucleic acid-encapsulating polymer micelle complex is formed of a block copolymer containing an uncharged hydrophilic polymer chain block and a cationic polymer chain block; and two single-stranded DNA molecules having mutually complementary base sequences of 1000 or more bases in length, double-stranded DNA of 1000 or more base pairs in length in which at least a part of a double helix structure is dissociated and forms a single-stranded structure, or one single-stranded DNA molecule of 1000 or more bases in length.
    Type: Grant
    Filed: August 5, 2014
    Date of Patent: August 14, 2018
    Assignee: Japan Science and Technology Agency
    Inventors: Kazunori Kataoka, Kensuke Osada, Theofilus Agrios Tockary
  • Patent number: 10022373
    Abstract: The present invention relates to a pharmaceutical composition comprising posaconazole and a carrier material, wherein the carrier material comprises a vinylpyrrolidone-vinyl acetate copolymer or a polymer containing ethylene glycol units. The present invention also relates to a method for the preparation of the pharmaceutical composition, a method for the prevention and/or treatment of fungal infections and related diseases in a mammal using the pharmaceutical composition, and a pharmaceutical formulation comprising the pharmaceutical composition.
    Type: Grant
    Filed: April 10, 2015
    Date of Patent: July 17, 2018
    Assignee: SINOTHERAPEUTICS INC.
    Inventors: Jiansheng Wan, Kun Li, Xiaoxi Sheng
  • Patent number: 10000447
    Abstract: Here described are compounds consisting of the structure (targeting molecule)m-linker-(targeting molecule)n, wherein the targeting molecule is a retinoid or a fat soluble vitamin having a specific receptor on the target cell; wherein m and n are independently 0, 1, 2 or 3; and wherein the linker comprises a polyethylene glycol (PEG) or PEG-like molecule, as well as compositions and pharmaceutical formulations including these compounds which are useful for the targeting and delivery of therapeutic agents; and methods of using these compositions and pharmaceutical formulations.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: June 19, 2018
    Assignee: Nitto Denko Corporation
    Inventors: Yoshiro Niitsu, Joseph E. Payne, John A. Gaudette, Zheng Hou, Victor Knopov, Richard P. Witte, Mohammad Ahmadian, Loren A. Perelman, Yasunobu Tanaka, Violetta Akopian
  • Patent number: 9988517
    Abstract: Microsphere compositions containing a mixture of at least two materials with same or differing phases are described. The materials have differing optical dispersion curves that intersect at at least one particular wavelength exhibiting the Christiansen effect. The materials may be encompassed by a microsphere, which may also include a separation entity.
    Type: Grant
    Filed: June 5, 2012
    Date of Patent: June 5, 2018
    Assignee: EMPIRE TECHNOLOGY DEVELOPMENT LLC
    Inventors: Sung-Wei Chen, Christopher J. Rothfuss
  • Patent number: 9982090
    Abstract: The present invention relates to a method for manufacturing polydioxanone particles (PDO) for a filler, more particularly to a method for manufacturing polydioxanone particles, which includes a step of mixing a solution of polydioxanone dissolved in a perfluoroalcohol with a polymer emulsion containing a polyethylene oxide-polypropylene oxide-polyethylene oxide terpolymer at a predetermined ratio to generate polydioxanone particles and then recovering the polydioxanone particles through aging and washing. The polydioxanone particles manufactured by the manufacturing method of the present invention can be favorably used as an injection for regenerating skin tissues.
    Type: Grant
    Filed: July 16, 2015
    Date of Patent: May 29, 2018
    Assignee: ULTRA V CO., LTD.
    Inventors: Myung Choi, Sang Jin Kim, Byeung Mo Chang, Michael Gilbert Douglas, Han Jin Kwon
  • Patent number: 9925212
    Abstract: The present invention generally relates to methods of treating hypertension (HTN) in patients in need thereof wherein the patient optionally further suffers from chronic kidney disease (CKD) or Type II diabetes mellitus (T2DM). The invention also relates to methods of treating hyperkalemia in a patient in need thereof, wherein the patient suffers from CKD, T2DM or HTN and are optionally being treated with an effective amount of a renin-angiotensin-aldosterone system (RAAS) agent. The invention also relates to methods of treating kidney disease in a patient in need thereof, wherein the patient is optionally being treated with an effective amount of a renin-angiotensin-aldosterone system (RAAS) agent. The methods can comprise administering an effective amount of a potassium-binding agent to the patient to lower the patient's blood pressure and/or increase or stabilize the patient's kidney function.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: March 27, 2018
    Assignee: Relypsa, Inc.
    Inventors: Gerrit Klaerner, Lance Berman
  • Patent number: 9907977
    Abstract: The present disclosure relates to the cross-linking of eye tissue. Embodiments of the disclosure relate to the activation of a photosensitizer and/or nanoparticles for the cross-linking of eye tissue.
    Type: Grant
    Filed: May 13, 2015
    Date of Patent: March 6, 2018
    Assignee: Novartis AG
    Inventor: Katrin Skerl